{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:59:42Z","timestamp":1767193182603},"reference-count":47,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T00:00:00Z","timestamp":1467590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec><jats:label \/><jats:p>Metastatic cancer remains a devastating disease that threatens to disrupt entire family structures creating economic and psychosocial stress. Fortunately, great strides have resulted in improved therapies over the years but at a huge social\u2010economic cost. The economic burden has risen greatly and carries with it new ethical concerns when deciding treatment. Here, we discuss the financial and ethical challenges that oncologists and their patients face in the era of novel treatment strategies. <jats:italic>J. Surg. Oncol. 2016;114:323\u2013328<\/jats:italic>. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jso.24333","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T04:37:09Z","timestamp":1467693429000},"page":"323-328","source":"Crossref","is-referenced-by-count":5,"title":["The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer"],"prefix":"10.1002","volume":"114","author":[{"given":"Muhammad Kashif","family":"Riaz","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology University of Cincinnati Medical Center Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bal","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology University of Cincinnati Medical Center Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha","family":"Wise\u2010Draper","sequence":"additional","affiliation":[{"name":"Assistant Professor of Medicine, Division of Hematology\/Oncology, Head and Neck Oncology\/Experimental Therapeutics, Associate Hematology\/Oncology Fellowship Director University of Cincinnati Cancer Institute Cincinnati Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,4]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"Cancer facts and figures 2016","year":"2016"},{"key":"e_1_2_7_3_1","unstructured":"US Food and Drug administration:Hematology\/oncology (cancer) approvals & safety notifications. (http:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm279174.htm)"},{"key":"e_1_2_7_4_1","unstructured":"MunroD: \u201cU.S. Healthcare Spending On Track To Hit $10 000 Per Person This Year.\u201d Forbes. Jan. 4 2015.http:\/\/www.forbes.com\/sites\/danmunro\/2015\/01\/04\/u\u2010s\u2010healthcare\u2010spending\u2010on\u2010track\u2010to\u2010hit\u201010000\u2010per\u2010person\u2010this\u2010year\/"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2015.0600"},{"key":"e_1_2_7_6_1","unstructured":"Mike Wall:Space.com. Should NASA Ditch Manned Missions to Mars? August 5 2012(http:\/\/www.space.com\/16918\u2010nasa\u2010mars\u2010human\u2010spaceflight\u2010goals.html)"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq495"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1002\/cncr.28321","article-title":"Market spiral pricing of cancer drugs","volume":"119","author":"Light DW","journal-title":"Cancer"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy\u2010refractory wild\u2010type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open\u2010label, non\u2010inferiority phase 3 study","volume":"15","author":"Price TJ","journal-title":"Lancet Oncol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv268"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70181-5"},{"key":"e_1_2_7_14_1","unstructured":"World Health Orginazation: Division of mental health and prevention of substance abuse measuring quality of life 1997 (http:\/\/www.who.int\/mental_health\/media\/68.pdf)"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/913848"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2553-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.2378"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091023"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2016.01.012"},{"key":"e_1_2_7_21_1","unstructured":"LichtenbergFR DuflosG:\u201cTime release: The effect of patent expiration on U.S. drug prices marketing and utilization by the public.\u201dCenter for Medical Progress at the Manhattan Institute October. 2009."},{"key":"e_1_2_7_22_1","volume-title":"Drug goes from $13.50 a tablet to $750, Overnight","author":"Pollack A","year":"2015"},{"key":"e_1_2_7_23_1","volume-title":"In cancer care, cost matters","author":"Bach P","year":"2012"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9525"},{"key":"e_1_2_7_25_1","first-page":"0401","article-title":"Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value","volume":"13","author":"Miksad RA","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_26_1","unstructured":"US Food and Drug administration:Full prescribing information OPDIVO. Reference ID: 3827356 (http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125554s002lbl.pdf)"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00021-2"},{"key":"e_1_2_7_28_1","unstructured":"Value as a Guiding Principle of Cancer Care Delivery Richard L. Schilsky M.D. FACP FASCO Chief Medical Officer ASCO."},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2015.7"},{"key":"e_1_2_7_30_1","unstructured":"ClinicalTrials.govIdentifier: NCT01543776.Food effect study of abiraterone acetate for treatment of patients with castration\u2010resistant prostate cancer."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"e_1_2_7_32_1","first-page":"871","article-title":"Successful administration of regorafenib to a metastatic colon cancer patient with impaired performance status by reducing the initial dose","volume":"42","author":"Nishitai R","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.9852"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.8860"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1007168"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1998.00211.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462310001194"},{"key":"e_1_2_7_38_1","first-page":"47","article-title":"Is it time to take a harder look at the QALY","volume":"5","author":"Brower A","year":"2008","journal-title":"Biotechnol Healthc"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.9569"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1919-y"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000231"},{"key":"e_1_2_7_42_1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V124.21.738.738","article-title":"What is the most cost\u2010effective strategy for treating newly diagnosed chronic phase chronic myeloid leukemia (CML) after imatinib loses patent exclusivity","volume":"124","author":"Larson RA","year":"2014","journal-title":"Blood"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.0401"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107255"},{"key":"e_1_2_7_45_1","unstructured":"Institute for clinical and economic review.ICER releases evidence report on treatments for multiple myeloma 2016.http:\/\/icer\u2010review.org\/announcements\/icer\u2010releases\u2010evidence\u2010report\u2010on\u2010treatments\u2010for\u2010multiple\u2010myeloma"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31817c6a4d"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.06.001"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.3316"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.24333","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.24333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T23:19:49Z","timestamp":1696461589000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.24333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,4]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1002\/jso.24333"],"URL":"https:\/\/doi.org\/10.1002\/jso.24333","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,4]]}}}